# St John's Wort in the treatment against Major Depression Disorder

## Authors

- Sajad Ahmad Bhat ([ORCID](https://orcid.org/0000-0002-6782-5459)) — Section of Genetics, Department of Zoology, Faculty of Life Science, Aligarh Muslim University, Aligarh, India
- Ab Latif Wani ([ORCID](https://orcid.org/0000-0003-1818-6133)) — Section of Genetics, Department of Zoology, Faculty of Life Science, Aligarh Muslim University, Aligarh, India
- Anjum Ara ([ORCID](https://orcid.org/0000-0003-1582-1576)) — Section of Genetics, Department of Zoology, Faculty of Life Science, Aligarh Muslim University, Aligarh, India

## Article information

- **Journal:** The Ulutas Medical Journal (Ulutas Med J), ISSN 2149-388X
- **Issue:** Volume 1, Issue 2 (2015), pages 16–21
- **Article type:** Review Article
- **Published online:** 2015-06-24
- **DOI:** [10.5455/umj.20150418040725](https://doi.org/10.5455/umj.20150418040725)
- **Licence:** [CC BY-NC 4.0](https://creativecommons.org/licenses/by-nc/4.0/)
- **Article page:** https://www.ulutasmedicaljournal.com/?mno=182816
- **PDF:** https://www.ulutasmedicaljournal.com/pdf/182816.pdf

## Abstract

Depression is a complex mood disorder with many types and treated in a number of ways. There are large numbers of synthetic drugs which are used in treating major depressive disorder. However they are also found to have bad impact on the health of a patient. Depression is multifactorial phenomenon, in which hormonal and neurotransmitter imbalance plays imperative role in its causation. Though large number of pharmaceutical drugs is available but they also pose serious threat due to extended use as serious side effects also develop. It is very important to look for antidepressants from natural sources which are advantageous, less hazardous and has least side effects on human health. This article aims to focus on specific natural antidepressant St John's Wort and how it can act as alternative medicine exhibiting the potential for the treatment of depression.

## Keywords

Depression; Natural Antidepressants; St John Worts

## How to cite

Bhat SA, Wani AL, Ara A. St John's Wort in the treatment against Major Depression Disorder. Ulutas Med J. 2015;1(2):16-21. doi:10.5455/umj.20150418040725

## References

1. Kruijshaar ME, Barendregt J, Vos T, et al. Life time prevalence estimates of major depression: an indirect estimation method and quantification of recall bias. Eur J Epidemiol. 2005; 20:103-111. https://doi.org/10.1007/s10654-004-1009-0
2. Smith AJ, Sketris I, Cooke C, et al. A comparison of antidepressant use in Nova Scotia, Canada and Australia. Pharmacoepidemiol Drug Saf. 2008; 17:697-706. https://doi.org/10.1002/pds.1541
3. Tierney LM, McPhee SJ, Papadakis MA, eds. Current Medical Diagnosis & Treatment. 45th ed. SanFrancisco, CA: McGraw-Hill; 2006:1065-1066.
4. Mann JJ. The medical management of depression. N Engl J Med. 2005; 353:1819-1834. https://doi.org/10.1056/nejmra050730
5. Bhat SA, Wani AL, Ara A, Saidullah B. An epidemiological study on depression and its comorbidity. Int J of Latest Res Science and Tech. 2014; 3(4): 12-17.
6. Wani AL, Ara A, Bhat SA. “Blood Injury and Injection Phobia: The Neglected One,” Behav Neurol 2014; vol. Article ID 471340, 7 pages, 2014. doi:10.1155/2014/471340.
7. Hansson L. Quality of life in depression and anxiety. Int Rev Psychiatry 2002; 14:185-189. https://doi.org/10.1080/09540260220144966
8. Andrews G, Titov N. Depression is very disabling. Lancet. 2007;370:808-809. https://doi.org/10.1016/s0140-6736(07)61393-2
9. Tomas K, Coleman P. Use of complementary or alternative medicine in a general population in Great Britain. Results from the National Omnibus survey. J Public Health. 2004;26:152 -157.
10. Zhou SF, Lai X. An update of clinical drug interactions with the herbal antidepressant St. John’s wort. Curr Drug Metab. 2008; 9:394-409. https://doi.org/10.2174/138920008784746391
11. Tindle HA, Davis RB, Phillips RS, Eisenberg DM.Trends in the use of complementary and alternative medicine by US adults: 1997-2002. Altern ther Health Med. 2005; 11:42-49.
12. Mehta, Sweety (2012-12-18). Pharmacognosy of St john’s Wort. Pharmaxchange.info. Retrieved 2014-02 -16.
13. Nathan, PJ. "Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology". Journal of psychopharmacology (Oxford, England). 2001;15(1):47–54. https://doi.org/10.1177/026988110101500109
14. Ernst E 1999 Second thoughts about safety of St John’s wort. Lancet 354; 2014-2016. https://doi.org/10.1016/s0140-6736(99)00418-3
15. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W & Melchart D. St John’s wort for depression - an overview and meta- analysis of randomised clinical trials. Br Med J. 1996; 313 253-258. https://doi.org/10.1136/bmj.313.7052.253
16. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug–drug interactions: an update. Curr Drug Metabl. 2002; 3:13–37. https://doi.org/10.2174/1389200023338017
17. Mueller SC, Uehleke B,Woehling H, et al. Effect of St John’s wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther. 2004;75:546–557. https://doi.org/10.1016/j.clpt.2004.01.014
18. Izzo AA. Drug interactions with St. John’s wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther.2004; 42: 139–148. https://doi.org/10.5414/cpp42139
19. Muller WE, Singer A, Wonnermann M, Hafner U, Rolli M and Schafer C, Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract, Pharmacopsychiatry. 1998; Suppl (1) 16-21 https://doi.org/10.1055/s-2007-979341
20. Chatterjee SS, Bhattacharya SK, Wonnermann M, Singer A and Muller WE, Hyperforin as a possible antidepressant component of Hypericum extract, Life Sci. 1998; 63: 499-510.
21. Barnes J, Anderson LA and Phillipson JD, St. John’s wort (H. perforatum L): a review of its chemistry, pharmacology and clinical properties, J Pharm Pharmacol. 2001:53: 583-600. https://doi.org/10.1211/0022357011775910
22. Singer A, Wonnermann M and Muller WE, Hyperforin, a major antidepressant constituent of St. John’s wort, inhibits serotonin uptake by elevating free intracellular Na+, J Pharmacol Exp Ther. 1999: 290: 1363-1368. https://doi.org/10.1016/s0022-3565(24)35043-8
23. Calapai G, Crupi A, Firenzuoli F, Inferrera G, Squadrito F, Parisi A, De Sarro G and CaputiA, Serotonin, norepinephrine and dopamine involvement in the antidepressant action of Hypericum perforatum. Pharmacopsychiatry, 2001; 34(2): 45-49. https://doi.org/10.1055/s-2001-15180
24. Yu PH, Effect of the Hypericum perforatum on serotonin t urnover in the mouse brain, Pharmacopsychiatry. 2000; 33(2): 60-65. https://doi.org/10.1055/s-2000-7970
25. Muller WE, Rolli M, Schafer C and Hafner U, Effects of Hypericum extract in bioc hemical models of antidepressant activity, Pharmacopsychiatry. 1997; 30(2):102-107.
26. Muller WE, Singer A and Wonnemann M, Mechanism of action of St. John’s wort extract, Schweiz Rundsch Med Prax. 2000; 89(50): 2111-2121.
27. Sarris J. St. John's Wort for the treatment of psychiatric disorders. Psychiatr Clin North Am. 2013; 36(1):65-72. Sajad Ahmad Bhat, et al. Major Depression Disorder Treatment https://doi.org/10.1016/j.psc.2013.01.004
28. Pirotta M, Willis K, Carter M, Forsdike K, Newton D, Gunn J. 'Less like a drug than a drug': The use of St John's Wort among people who self-identify as having depressionand/or anxiety symptoms. Complement Ther Med. 2014; 22(5):870-6. https://doi.org/10.1016/j.ctim.2014.07.007
29. Sell TS, Belkacemi T, Flockerzi V, Beck A. Protonophore properties of hyperforin are essential for its pharmacological activity. Sci Rep. 2014;4:7500. https://doi.org/10.1038/srep07500
30. Tian J, Zhang F, Cheng J, Guo S, Liu P, Wang H. Antidepressant-like activity of adhyperforin, a novel constituent of Hypericum perforatum L. Sci Rep. 2014; 4:5632. https://doi.org/10.1038/srep05632
31. Vance KM, Ribnicky DM, Hermann GE, Rogers RC. St. John's Wort enhances the synaptic activity of the nucleus of the solitary tract. Nutrition. 2014; 30(7-8 Suppl): S37-42. https://doi.org/10.1016/j.nut.2014.02.008
32. Bukhari IA, Dar A.Behavioral profile of ypericum perforatum (St. John's Wort) extract. A comparison with standard anti depressants in animal models of depression. Eur Rev Med Pharmacol Sci. 2013; 17(8):1082-1089.
33. Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD000448. https://doi.org/10.1002/14651858.cd000448.pub3
34. Bouron A, Lorrain E. Cellular and molecular effects of the antidepressant hyperforin on brain cells: Review of the literature. Encephale. 2014; 40(2):108-13.
35. Husain GM, Chatterjee SS, Singh PN, Kumar V. Beneficial effect of Hypericum perforatum on depression and anxiety in a type 2 diabetic rat model. Acta Pol Pharm. 2011;68(6):913-8.
36. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005; 352 (11): 1112– 20. https://doi.org/10.1056/nejmra041867
37. Gillman PK. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry.2011; 59 (11): 1046– 51.
38. Is "Serotonin toxicity: a practical approach to diagnosis and treatment". Med J Aust. 2007; 187 (6): 361-5.
39. Strawn JR, Keck PE, Caroff SN. "Neuroleptic malignant syndrome". Am J Psychiatry. 2007; 164 (6): 870–6. https://doi.org/10.1176/ajp.2007.164.6.870
